PIP Search Page

Displaying 61 - 80 of 122

PIPS Search Results
PIP Number	Active Substance	Conditions / Indications	Invented Name	Therapeutic area	Decision Type	Compliance Check Sort descending	Date Published
MHRA-100634-PIP01-22	Ceralasertib	Treatment of lung carcinoma (small cell and non-small cell carcinoma)		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	02/02/2023
MHRA-100186-PIP01-21	depemokimab	Treatment of chronic rhinosinusitus with nasal polyps (CRSwNP)	Depemokimab	Pneumology - Allergology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100316-PIP02-22	latozinemab	Treatment of Amyotrophic lateral sclerosis		Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100632-PIP01-22-M01 (update)	FLUCICLOVINE (18F)	Diagnosis of amino acid metabolism in solid malignant tumours	Axumin Axumin Axumin Axumin Axumin Axumin Axumin Axumin	Diagnostic Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100493-PIP01-22	BI 765128 - humanized monoclonal antibody of IgG1 subtype targeting NRP1	Diabetic retinopathy		Ophthamology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100565-PIP01-22	MDM2-p53 antagonist	Treatment of liposarcoma		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100555-PIP01-22	vepsitamab	Treatment of gastric cancer and gastro-oesophageal junction cancer Treatment of colorectal carcinoma Treatment of pancreatic cancer		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100599-PIP01-22	Flortaucipir F18	Diagnosis of Alzheimer's disease	Tauvid Tauvid	Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100583-PIP01-22	SACITUZUMAB GOVITECAN	Treatment of lung carcinoma (small-cell and non-small-cell carcinoma)	Trodelvy Trodelvy Trodelvy	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100602-PIP01-22	monalizumab	Treatment of lung cancer		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100603-PIP01-22	Oleclumab	Treatment of lung cancer Treatment of pancreatic cancer		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100577-PIP01-22	ziltivekimab	Treatment of heart failure	Not available at present	Cardiovascular Diseases	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100587-PIP01-22	lusvertikimab	Treatment of Sjögren’s syndrome		Immunology -Rheumatology-Transplantation	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100598-PIP01-22	Cobolimab	Treatment of lung cancer	Not available at present	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100684-PIP01-22	Clazakizumab	Prevention of cardiovascular events in patients with atherosclerosis	Not available at present	Cardiovascular Diseases	W: decision granting a waiver in all age groups for the listed condition(s).	No	30/06/2023
MHRA-100733-PIP01-22	Botulinum toxin type E	Treatment of skin wrinkling		Dermatology	W: decision granting a waiver in all age groups for the listed condition(s).	No	30/06/2023
MHRA-100699-PIP01-22-M01 (update)	DIROXIMEL FUMARATE	Treatment of Multiple Sclerosis	Vumerity Vumerity Vumerity	Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	30/06/2023
MHRA-100029-PIP01-21-M01 (update)	RECOMBINANT REPLICATION-INCOMPETENT ADENOVIRUS SEROTYPE 26 VECTOR ENCODING THE SARS-COV-2 SPIKE PROTEIN PER.C6 CELL LINE COVID-19 vaccine (Ad26.COV2-S [recombinant])	Prevention of coronavirus disease-2019 (COVID-19)	COVID-19 vaccine Janssen Jcovden (previously COVID-19 Vaccine Janssen)	Infectious diseases Vaccines	W: decision granting a waiver in all age groups for the listed condition(s).	No	30/06/2023
MHRA-100740-PIP01-22	Xevinapant	Treatment of head and neck epithelial malignant neoplasms	Not available at present	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	30/06/2023
MHRA-100738-PIP01-22	PEMIGATINIB	Treatment of myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement	Pemazyre Pemazyre Pemazyre Pemazyre Pemazyre Pemazyre Pemazyre Pemazyre Pemazyre Pemazyre Pemazyre Pemazyre	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	24/08/2023

Download XLSX

Search Filters: